Biomarkers and imaging: Physics and chemistry for noninvasive analyses

Bioanalysis

Volumn 1, Issue 2, 2009, Pages 321-356

  Moyer, Brian R ^a   Barrett, John A ^b  

^a BR Moyer and Associates LLC   (United States)

^b A Subsidiary of Lantheus Holdings   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ALZHEIMER DISEASE; ANIMAL; BRAIN; CLINICAL TRIAL (TOPIC); DIAGNOSTIC IMAGING; DRUG SCREENING; HUMAN; METABOLISM; MOUSE; PATHOLOGY; PHARMACOKINETICS; RABBIT; RAT; RESEARCH; REVIEW; SCINTISCANNING;

ALZHEIMER DISEASE; ANIMALS; BIOLOGICAL MARKERS; BRAIN; CLINICAL TRIALS AS TOPIC; DIAGNOSTIC IMAGING; DRUG EVALUATION, PRECLINICAL; HUMANS; MICE; PHARMACOKINETICS; RABBITS; RATS; RESEARCH;

EID: 79957942896     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.09.30     Document Type: Review

References (114)

1. LaBaer J. So, you want to look for biomarkers (introduction to the special biomarkers issue). J. Proteome Res. 4, 1053-1059 (2005).
2. Colburn WA. Surrogate markers and clinical pharmacology. J. Clin. Pharmacol. 35(5), 441-442 (1995)
3. Comment 464-470 (1995).
4. Colburn WA. Selecting and validating biologic markers for drug development. J. Clin. Pharmacol. 37(5), 355-362 (1997).
5. Daniels MJ, Hughes MD. Meta-analysis for the evaluation of potential surrogate markers. Stat. Med. 16(17), 1965-1982 (1997).
6. De Gruttola V, Fleming T, Lin DY, Coombs R. Perspective: validating surrogate markers-are we being naive? J. Infect. Dis. 175(2), 237-246 (1997).
7. Deyton L. Importance of surrogate markers in evaluation of antiviral therapy for HIV infection. JAMA 276(2), 159-160 (1996).
8. Ellenberg SS, Hamilton JM. Surrogate endpoints in clinical trials: cancer. Stat. Med. 8(4), 405-413 (1989).
9. Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat. Rev. Drug Discov. 2, 566-580 (2003).
10. DeMeyer G, Shapiro F. Biomarker development. The road to clinical utility Curr. Drug Discov. 12, 23-27 (2003).
11. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann. Intern. Med. 125(7), 605-613 (1995)
12. Comment 126(8), 667 (1996).
13. Freedman LS, Graubard BI, Schatzkin A. Statistical validation of intermediate endpoints for chronic diseases. Stat. Med. 11(2), 167-178 (1992).
14. Hughes MD, DeGruttola V, Welles SL. Evaluating surrogate markers. J. Acquir. Immune Defc. Syndr. Hum. Retrovirol. 10(Suppl. 2), S1-S8 (1995).
15. Prentice RL. Surrogate endpoints in clinical trials: defnition and operational criteria. Stat. Med. 8, 431-440 (1989).
16. Meadows SK, Dressman HK, Muramoto GG et al. Gene expression signatures of radiation response are specifc, durable and accurate in mice and humans. PLoS Med. 3, 690-701 (2008).
17. Dressman H, Muramoto GG, Chao NJ et al. Gene expression signatures that predict radiation exposure in mice and humans. PLoS Med. 4, 1-9 (2007).
18. Marchetti, F, Coleman MA, Jones IM, Wyrobek AJ. Candidate protein biodosimeters of human exposure to ionizing radiation. Int. J. Rad. Biol. 82, 605-639 (2006).
19. Okunieff P, Chen Y, Maguire DJ, Huser AK. Molecular markers of radiation-related normal tissue toxicity. Cancer Metastasis Rev. 27(3), 363-374 (2008).
20. Corbett JR, Ficaro EP. Gated SPECT and the visual gold standard: gold standard or not? J. Nucl. Med. 42(11), 1639-1642 (2004).
21. Christian PE, Bernier DBR, Langham JK (Eds). Nuclear Medicine and PET. Technology and Techniques (5th Edition). Mosby Press, MO, USA (2004).
22. Valk P, Bailey DL, Townsend DW, Maisey MM (Eds). Positron Emission Tomography: Basic Science and Clinical Practice. Springer, London, UK (2003).
23. Phelps ME (Ed.). PET: Molecular Imaging and its Biological Applications. Springer-Verlag, NY, USA (2004).
24. 201TlCl/ 123I-BMIPP dual-myocardial SPECT for patients with non-ST segment elevation myocardial infarction. Ann. Nucl. Med. 22(5), 363-369 (2008).
25. Cercignani M, Bozzali M, Iannucci G, Comi G, Filippi M. Magnetization transfer ratio and mean diffusivity of normal appearing white and grey matter from patients with multiple sclerosis. J. Neurol. Neurosurg Psychiatry 70, 311-317 (2001).
26. Filippi M, Horsfeld MA, Ader HJ et al. Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis. Ann. Neurol. 43, 499-506 (1998).
27. Brooks DJ. Neuroimaging in Parkinson disease. NeurRx 1(2), 243-254 (2004).
28. 11C] tetrabenazine. Synapse 14, 128-131 (1993).
29. 11C PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 68, 1205-1212 (2007).
30. 18F]-fuoro-2-deoxy-D- glucose uptake at PET. Radiology 196, 167-173 (1995).
31. Pineiro R, Pendlebury S, Johansen-Berg H, Matthews PM. BOLD signal in stroke altered hemodynamic responses in patients after subcortical stroke measured by functional MRI. Stroke 33, 103-109 (2002).
32. Savage JRK, Papworth DG. Comment on the ratio of chromosome-type dicentric interchanges to centric rings for track-clustered compared with random breaks. Radiation Res. 146, 236-240 (1996).
33. Sinha P, Conrad GR, Shyamashree SS. Localization of In-111 white blood cells in rhabdomyolysis. Clin. Nucl. Med. 29, 367-369 (2004).
34. Eckelman WC. The use of PET and knockout mice in the drug discovery process. Drug Discovery Today 8, 404-410 (2003).
35. Smith JJ, Sorenson AG, Thrall JH. Biomarkers in imaging: realizing radiology's future. Radiology 227, 633-638 (2003).
36. Therasse P. Measuring the clinical response. What does it mean? Eur. J. Cancer 38, 1817-1823 (2002).
37. Friedland GW, Thurber BD. Perspective: the birth of CT. Am. J. Roent. 167, 1365-1370 (1996).
38. Caro, LG, Van Tubergen RP. High-resolution autoradiography I. Methods. J. Cell Biol. 15, 173-182 (1962).
39. Solon EG, Kraus L. Appraisal of state-of-the-art: quantitative whole-body autoradiography in the pharmaceutical industry. Survey results on study design, methods, and regulatory compliance. J. Pharm. Toxicol. Meth. 46, 73-81 (2002).
40. Solon E. Correspondence: continued discussion of quantitative whole-body autoradiography in the pharmaceutical industry. Survey results on study design, methods and regulatory compliance. J. Pharm. Toxicol. Meth. 48, 187-189 (2002).
41. Solon E. Autoradiography: high resolution molecular imaging in pharmaceutical discovery and development. Expert Opin. Drug Discov. 2(4), 1-12 (2007).
42. Johnston RF, Pickett SC, Barker DL. Autoradiography using storage phosphor technology. Electrophoresis 11, 355-360 (1990)
43. Wagner H. History notes. Hal Anger: nuclear medicine's quiet genius. J. Nucl. Med. 44, N26-N34 (2003).
44. Thakur ML. Radiolabeled peptides: now and the future. Nucl. Med. Comm. 16, 724-732 (1995).
45. Cogo A, Lensing AW, Koopman MMW et al. Compression ultrasound for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort study. BMJ 316, 17-20 (1998).
46. Bates SM, Lister-James J, Julian JA et al. Imaging characteristics of a novel technetium Tc-99m-labeled platelet glycoprotein IIb/IIIa receptor antagonist in patients with acute deep vein thrombosis or a history of deep vein thrombosis. Arch. Intern. Med. 163, 452-456 (2003).
47. Taillefer R, Edell S, Innes G, Lister-James J. Acute thromboscintigraphy with 99mTc-apcitide: results of the Phase III multicenter clinical trial comparing 99mTc-apcitide scintigraphy with contrast venography for imaging acute DVT. J. Nucl. Med. 41, 1214-1223 (2000)
48. Molecular imaging of cancer: from molecules to humans. J. Nucl. Med. 49(Suppl. 2), S1-S195 (2008).
49. Pichler BJ, Wehrl HF, Judenhofer MS. Latest advances in molecular imaging instrumentation. J. Nucl. Med. 49, (Suppl.) 2:5S-23S (2008).
50. Vastenhouw B, Beekman F. Submillimeter total-body murine imaging with U-SPECT-I. J. Nucl. Med. 48, 487-493 (2007).
51. Shapiro D, Thibault P, Beetz T et al. Biological imaging by soft X-ray diffraction microscopy. Proc. Natl Acad. Sci. USA 102, 15343-15346 (2005).
52. 11C-methyl]-(-)-cocaine PET studies in human subjects. J. Cereb. Blood Flow Metab. 10, 740-747 (1990).
53. 18F)2-fuoro-2-deoxy-D-glucose: validation of method. Ann. Neurol. 6, 371-88 (1979)
54. 18F-FDG input function in mice by use of dynamic small-animal PET and minimal blood sample data. J. Nucl. Med. 48, 2037-2045 (2007).
55. Krohn KA, Muzi M, Spence AM. What is in a number? The FDG lumped constant in the rat brain. J. Nucl. Med. 48, 5-7 (2007).
56. Huang SC. The anatomy of SUV (standardized uptake value). Nucl. Med. Biol. 27, 643-646 (2000).
57. Keyes JW SUV: standardized uptake or silly useless value? J. Nucl. Med. 36, 1836-1839 (1995).
58. Sandella A, Ohlsson T, Erlandsson K, Strand SE. An alternative method to normalize clinical FDG studies. J. Nucl. Med. 39(3), 552-555 (1998)
59. Sossi V Cutting edge brain imaging with positron emission tomography. Neuroimaging Clin. N. Am. 17, 427-440 (2007).
60. 11C]PIB in a nondemented population. Potential antecedent marker of Alzheimer disease. Neurology 67, 446-452 (2006).
61. Ylera F, Lurz R, Erdmann VA, Fürste JP. Selection of RNA aptamers to the Alzheimer's disease amyloid peptide. Biochem. Biophys. Res. Comm. 290, 1583-1588 (2002).
62. Dougan H, Weitz JI, Stafford AR et al. Evaluation of DNA aptamers directed to thrombin as potential thrombus imaging agents. Nucl. Med. Biol. 30, 61-72 (2003).
63. Gambhir SS. Using radiolabeled DNA as an imaging agent to recognize protein targets. J. Nucl. Med. 47(4), 557-558 (2006).
64. Heiss W-D, Herholz K. Brain receptor imaging. J. Nucl. Med. 47, 302-312 (2006).
65. Williams DL, Minshew NJ. Understanding autism and related disorders: what has imaging taught us? Neuroimaging Clin. N Am. 17, 495-509 (2007).
66. Esposito G, Giovacchini G, Liow J-S et al. Imaging neuroinfammation in Alzheimer's disease with radiolabeled arachidonic acid and PET J. Nucl. Med. 49, 1414-1421 (2008)
67. Diehn M, Nardini C, Wang DS et al. Identifcation of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc. Natl Acad. Sci. 105, 5213-5218 (2008).
68. Arndt JW, Van der Sluys VA, Blok D et al. Prospective comparative study of technetium 99m-WBCs and indium-111 granulocytes for examination of patients with infammatory bowel disease. J. Nucl. Med. 34, 1052-1057 (1993).
69. 64Cu-Pyruvaldehyde-Bis(N4-Methylthiosemicarbazone) for microPET imaging. Mol. Imag 7(1), 1-11 (2008).
70. 18F-FDG for differentiating tumor from infammation in a rodent model. J. Nucl. Med. 45, 695-700 (2004).
71. 18F-FDG PET in esophageal cancer. J. Nucl. Med. 46, 400-404 (2005).
72. 99mTc-labelled leukotriene B4 receptor antagonist for scintigraphic detection of infection in rabbits. Nucl. Med. Comm. 21(11), 1043-1050 (2000).
73. Thurner MM, Sundgren PC. Imaging of slow viruses. Neuroimaging Clin. N. Am. 18, 133-148 (2008).
74. Charlton J, Sennello J, Smith D. In vivo imaging of infammation using an aptamer inhibitor of human neutrophil elastase. Chem. Biol. 4, 809-816 (1997).
75. Hansen CL, Goldstein RA, Akinboboye OO et al. Myocardial perfusion and function: single photon emission computed tomography. J. Nucl. Cardiol. 14, E39-E60 (2007).
76. Machac J, Bacharach SL, Bateman TM et al. Positron emission tomography myocardial perfusion and glucose metabolism imaging. J. Nucl. Cardiol. 13, E121-E151 (2006).
77. Santana CA, Folks RD, Garcia EV et al. Quantitative 82Rb PET/CT: development and validation of myocardial perfusion database. J. Nucl. Med. 48, 1122-1128 (2007).
78. Yamada T, Matsumori A, Tamaki S, Sasayama S. Myosin light chain I grade: a simple marker for the severity and prognosis of patients with acute myocardial infarction. Am. Heart J. 135(2 Pt 1), 329-334 (1998).
79. Niven R, Pearlman R, Wedeking T et al. Biodistribution of radiolabeled lipid-DNA complexes and DNA in mice. J. Pharm. Sci. 87(11), 1292-1299 (2000).
80. Jaffer FA, Nahrendorf M, Sosnovik D, Kelly KA, Aikawa E, Weissleder R. Cellular imaging of infammation in atherosclerosis using magnetofuorescent nanomaterials. Mol. Imaging 5, 85-92 (2006).
81. Henzlova MJ, Cerqueira MD, Taillefer R, Mahmarian JJ, Yao S-S. Stress protocols and tracers. J. Nucl. Cardiol. (2009) (In press).
82. Inoue T, Kato T, Uchida T et al. Local release of C-reactive protein from vulnerable plaque or coronary arterial wall injured by stenting. J. Am. Coll. Cardiol. 46(2), 239-245 (2005).
83. Orlova A, Nilsson FY, Wikman M et al. Comparative in vivo evaluation of iodine and technetium labels on anti-HER2 affbody for single photon imaging of HER2 expression in tumors. J. Nucl. Med. 47(3), 512-519 (2006).
84. Sampath L, Kwon S, Ke S et al. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer. J. Nucl. Med. 48, 1501-1510 (2007).
85. Krohn KA, Link JM, Mason R P. Molecular imaging of hypoxia. J. Nucl. Med. 49, S129-S148 (2008).
86. Wheeler KT, Wang L-M, Wallen CA et al. a-2 receptors as a biomarker of proliferation in solid tumours. Br. J. Cancer 82, 1223-1232 (2000).
87. Mankoff DA, Link JM, Linden HM, Sundararajan L, Krohn KA. Tumor receptor imaging. J. Nucl. Med. 49, S149-S163 (2008)
88. Stollman TH, Scheer MGW, Leenders WPJ et al. Specifc imaging of VEGF-A expression with radiolabeled anti-VEGF monoclonal antibody. Int. J. Cancer 122, 2310-2314 (2008).
89. Brown AP, Citrin DE, Camphausen KA. Clinical biomarkers of angiogenic inhibition. Cancer Metastases Rev. 27, 415-434 (2008).
90. Cai W, Chen X. Multimodality molecular imaging of tumor angiogenesis. J. Nucl. Med. 49, S113-S128 (2008).
91. Blankenburg FG. In-vivo detection of apoptosis. J. Nucl. Med. 49, S81-S95 (2008)
92. Hiller K-H, Waller C, Nahrendorf M, Bauer WR, Jakob PM. Assessment of cardiovascular apoptosis in the isolated rat heart by magnetic resonance molecular imaging. Mol. Imaging 5, 115-121 (2006).
93. Lu L, Samuelson L, Bergstrom M, Sato K, Fasth K-J, Langstrom B. Rat studies comparing C-11-FMAU, F-18 FLT and Br-76 BFU as proliferation markers. J. Nucl. Med. 43, 1688-1698 (2002).
94. Skarsgard LD, Harrison I. Dose dependence of the oxygen enhancement ratio (OER) in radiation inactivation of chinese hamster V79-171 Cells. Radiation Res. 127(3), 243-247 (1991)
95. Verheij M. Clinical biomarkers and imaging for radiotherapy-induced cell death. Cancer Metastases Rev. 27, 471-480 (2008).
96. 64Cu-ATSM: a comparison study with FDG. Nucl. Med. Biol. 30(5), 529-534 (2003).
97. Westbrook C, Roth CK, Talbot J. MRI In Practice (3rd Edition). Blackwell Publishing, UK (2005).
98. Evelhoch JL, Gillies RJ, Karczmar GS et al. Applications of magnetic resonance in model systems: cancer therapeutics: cancer Therapeutics Neoplasia 2, 152-165 (2000).
99. Mueller-Lisse UG, Scherr MK. Proton MR spectroscopy of the prostate. Eur. J. Radiol. 63(3), 351-360 (2007)
100. Baek H-M, Chen J-H, Nalcioglu O, Su M-Y. Letter to the editor. Choline as a biomarker for cell proliferation: do the results from proton MR spectroscopy show difference between HER2/neu positive and negative breast cancers? Int. J. Cancer 123(5), 219-1221 (2008).
101. Schlaug G, Seiwert B, Benfeld A, Edelman RR, Warach S. Time course of the apparent diffusion coeffcient (ADC) abnormality in stroke. Neurology 49, 113-119 (1997).
102. Chenevert TL, McKeever PE, Ross BD. Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. Clin. Cancer Res. 3, 1457-1466 (1997).
103. Morse DL, Galons JP, Payne CM et al. MRI-measured water mobility increases in response to chemotherapy via multiple cell death mechanisms. NMR Biomed. 20, 602-614 (2007).
104. Ross BD, Moffat BA, Lawrence TS et al. Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol. Cancer Ther. 2, 581-587 (2003).
105. Riess JG. Fluorocarbon-based injectable gaseous microbubbles for diagnosis and therapy. Curr. Opin. Colloild Interf. Sci. 8, 259-266 (2003).
106. Wirtzfeld LA, Wu G, Bygrave M et al. A new three-dimensional ultrasound microimaging technology for preclinical studies using a transgenic prostate cancer mouse model. Cancer Res. 65(14), 6337-6345 (2005).
107. Yang M, Baranov E, Jiang P et al. Whole-body optical imaging of green fuorescent protein-expressing tumors and metastases. Proc. Natl Acad. Sci. USA 97(3), 1206-1211 (2000).
108. Oyajobi BO, Munoz S, Kakonen R et al. Detection of myeloma in skeleton of mice by whole body optical fuorescence imaging. Med. Cancer Ther. 6(6), 1701-1708 (2007).
109. Medintz, IL, Testsuo-Uyeda H, Goldman ER, Mattoussi H. Quantum dot bioconjugates for imaging, labeling and sensing. Nat. Mater. 4, 435-446 (2005).
110. Michalet, X, Pinaud FF, Bentolila LA et al. Quantum dots for live cells, in vivo imaging, and diagnostics. Science 307, 538-544 (2005).
111. So M-K, Xu C, Loening AM, Gambhir SS, Rao J. Self-illuminating quantum dot conjugates for in-vivo imaging. Nat. Biotechnol. 24(1), 339-343 (2006).
112. Frangioni JV. Self-illuminating quantum dots light the way. Nat. Biotechnol. 24(3), 326-328 (2006)
113. Woodcock J. An FDA perspective on the drug development process. Food Drug Law J. 52(2), 145-161 (1997).
114. Lee JW, Devanarayan V, Barrett Y-C et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharmaceutical Res. 23(2), 312-328 (2006).